| Title |
Emerging Treatments in Cystic Fibrosis
|
|---|---|
| Published in |
Drugs, September 2012
|
| DOI | 10.2165/11318500-000000000-00000 |
| Pubmed ID | |
| Authors |
Andrew M. Jones, Jennifer M. Helm |
| Abstract |
There are a number of potential drugs for the treatment of cystic fibrosis (CF) currently undergoing clinical studies. A number of antibacterials formulated for delivery by inhalation are at various stages of study; these include dry-powder inhaler versions of colistin, tobramycin and ciprofloxacin, and formulations of azteonam, amikacin, levofloxacin, ciprofloxacin and fosfomycin/tobramycin for nebulization. Clinical trials of anti-inflammatory agents, including glutathione, phosphodiesterase-5 inhibitors such as sildenafil, oral acetylcysteine, simvastatin, methotrexate, docosahexaenoic acid, hydroxychloroquine, pioglitazone and alpha1-antitrypsin, are ongoing. Ion channel modulating agents, such as lancovutide (Moli1901, duramycin) and denufosol, which activate alternate (non-CF transmembrane regulator [CFTR]) chloride channels, and GS 9411, a sodium channel antagonist, are now at the stages of clinical study and if successful, will offer a new category of therapeutic agent for the treatment of CF. Correction of the underlying gene effect, either by agents that help to correct the dysfunctional CFTR, such as ataluren, VX-770 and VX-809, or by gene transfer (gene therapy), is a particularly exciting prospect as a new therapy for CF and clinical studies are ongoing. This article reviews the exciting potential drug treatments for CF currently being evaluated in clinical studies, and also highlights some of the challenges faced by research and clinical teams in assessing the efficacy of potential new therapies for CF. |
Mendeley readers
The data shown below were compiled from readership statistics for 136 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | <1% |
| Portugal | 1 | <1% |
| Unknown | 134 | 99% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 22 | 16% |
| Student > Ph. D. Student | 21 | 15% |
| Student > Master | 17 | 13% |
| Student > Bachelor | 17 | 13% |
| Student > Postgraduate | 8 | 6% |
| Other | 27 | 20% |
| Unknown | 24 | 18% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 33 | 24% |
| Agricultural and Biological Sciences | 20 | 15% |
| Biochemistry, Genetics and Molecular Biology | 16 | 12% |
| Chemistry | 13 | 10% |
| Pharmacology, Toxicology and Pharmaceutical Science | 7 | 5% |
| Other | 20 | 15% |
| Unknown | 27 | 20% |
Attention Score in Context
This research output has an Altmetric Attention Score of 24. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 09 April 2024.
All research outputs
#1,550,275
of 25,374,647 outputs
Outputs from Drugs
#148
of 3,464 outputs
Outputs of similar age
#9,587
of 189,087 outputs
Outputs of similar age from Drugs
#40
of 1,461 outputs
Altmetric has tracked 25,374,647 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 93rd percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,464 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 7.9. This one has done particularly well, scoring higher than 95% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 189,087 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 94% of its contemporaries.
We're also able to compare this research output to 1,461 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 97% of its contemporaries.